BBIO - BridgeBio Pharma Inc

-

$undefined

N/A

(N/A)

BridgeBio Pharma Inc NasdaqGS:BBIO BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.

Location: 3160 Porter Drive, Palo Alto, CA, 94304, United States | Website: https://bridgebio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

7.941B

Cash

540.6M

Avg Qtr Burn

-125.1M

Short % of Float

16.02%

Insider Ownership

4.95%

Institutional Own.

92.62%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
NULIBRY (Fosdenopterin) (BBP-870/ORGN001) Details
Molybdenum cofactor deficiency type A

Approved

Quarterly sales

Attruby™ (Acoramidis) (AG10) Details
Transthyretin Amyloid Cardiomyopathy

Approved

Quarterly sales

Infigratinib Details
Achondroplasia

Phase 3

Data readout

BBP-418 Details
Limb-Girdle Muscular Dystrophy

Phase 3

Data readout

Encaleret Details
Autosomal Dominant Hypocalcemia Type 1

Big Mover™

Susp. Mover™

Phase 3

Data readout

Infigratinib Details
Hypochondroplasia

Phase 2

Data readout

BBP-398 + OPDIVO Details
Solid tumor/s, Lung cancer, Non-small cell lung carcinoma

Phase 1/2

Data readout

BBP- 812 Details
Canavan disease

Phase 1/2

Update

BBO-8520 (KRASG12C inhibitor) Details
Non-small cell lung carcinoma, Lung cancer, Solid tumor/s

Phase 1

Data readout

BBO-10203 Details
Hyperglycemia

IND

Submission

BBP-631 Details
Congenital adrenal hyperplasia

Failed

Discontinued

Failed

Discontinued